PureTech Health plc (PRTCY)
| Market Cap | 451.06M +10.3% |
| Revenue (ttm) | 4.66M -3.5% |
| Net Income | -109.74M |
| EPS | -0.46 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,437 |
| Open | 18.56 |
| Previous Close | 18.61 |
| Day's Range | 18.32 - 18.56 |
| 52-Week Range | 14.50 - 19.92 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 4, 2026 |
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien... [Read more]
Financial Performance
Financial StatementsNews
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
BOSTON--(BUSINESS WIRE)--PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference.
PureTech Health Earnings Call Transcript: H2 2025
Refined strategy emphasizes operational efficiency, early spin-outs, and disciplined capital allocation. Cash runway extends through 2028, with major progress in Celea and Gallop clinical programs and a focus on returning capital to shareholders after significant inflows.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Announces Annual Results for Year Ended December 31, 2025
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2025.
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
BOSTON--(BUSINESS WIRE)--PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange.
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors.
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
BOSTON--(BUSINESS WIRE)--PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in R/R High-Risk Myelodysplastic Syndrome & R/R Acute Myeloid Leukemia.
PureTech Health: Notice of Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine.
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo (SPT-300).
PureTech Health Transcript: Leerink Global Healthcare Conference 2026
The conference highlighted a robust hub-and-spoke model driving innovation and value through spin-outs, with strong clinical progress in IPF and oncology. Deupirfenidone is poised for a pivotal phase 3 trial, and the company remains self-funded with significant future milestones expected.
PureTech to Present at the Leerink Partners Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Leerink Partners Global Healthcare Conference.
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
BOSTON--(BUSINESS WIRE)--PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone in IPF.
PureTech Health Transcript: 44th Annual J.P. Morgan Healthcare Conference
A diversified hub-and-spoke model drives innovation and financial returns by spinning out de-risked drug programs, with a strong track record of clinical and commercial success. Key assets Celea and Gallop are advancing to pivotal trials, while the company remains self-funded and focused on efficient capital allocation.
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference.
PureTech Appoints Robert Lyne as Chief Executive Officer
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innov...
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
BOSTON--(BUSINESS WIRE)--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis.
PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
BOSTON--(BUSINESS WIRE)--PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data for LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia.
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
BOSTON--(BUSINESS WIRE)--PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with IPF.
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
BOSTON--(BUSINESS WIRE)--PureTech Presents New Data from Deupirfenidone Phase 2b Open-Label Extension, Further Supporting Potential to Serve as New Standard of Care in IPF.
PureTech Health Earnings Call Transcript: H1 2025
Strong H1 2025 performance with $320M cash, reduced expenses, and focus on three core entities—Seaport, Gallop, and Celea. Key clinical milestones and external financings are expected to extend runway and drive value, with major data readouts and Phase III trial initiations ahead.
PureTech Health Quarterly report: H1 2025
PureTech Health has published its H1 2025 quarterly earnings report on August 28, 2025.
PureTech Health plc – Half-Year Report
BOSTON--(BUSINESS WIRE)--PureTech today announces its half-yearly results for the six months ended June 30, 2025.